Background-Although US cholesterol concentrations have dropped, Ϸ50% of adults have total cholesterol concentrations Ն5.18 mmol/L, putting them at "borderline-high risk" for heart disease. Whether the decline has continued into the 21st century is unknown. We assessed 20-year trends in cholesterol, hypercholesterolemia, lipid-lowering drug use, and cholesterol awareness, treatment, and control from Minnesota Heart Survey (MHS) data. Methods and Results-Five independent, cross-sectional, population-based surveys of 2500 to 5000 adults were conducted in the Minneapolis-St. Paul, Minn, area from 1980 to 2002. Mean (nonfasting) total cholesterol concentrations have continued a 20-year decline, punctuated by an intervening lull. Age-adjusted mean total cholesterol concentrations in 2000 to 2002 were 5.16 and 5.09 mmol/L for men and women, respectively (in 1980 to 1982, 5.49 and 5.38 mmol/L for men and women, respectively) However, the decline has not been uniform across all age groups. Middle-aged to older people have shown substantial decreases, but younger people have shown little overall change and recently had increased total cholesterol values. The mean prevalence of hypercholesterolemia in 2000 to 2002 was 54.9% for men and 46.5% for women and has decreased significantly for both during the study. Age-adjusted mean high-density lipoprotein cholesterol concentrations in 2000 to 2002 were 1.09 and 1.40 mmol/L for men and women, respectively, and were not different from the prior survey. Lipid-lowering drug use rose significantly for both sexes aged 35 to 74 years. Awareness, treatment, and control of hypercholesterolemia have increased; however, more than half of those at borderline-high risk remain unaware of their condition. Conclusions-Although hypercholesterolemia prevalence continued to fall, significant population segments still have cholesterol concentrations near or at the level of increased risk. (Circulation. 2005;112:3884-3891.)
C oronary heart disease (CHD) is the single largest cause of death in the United States, leading to Ͼ1 in every 5 deaths in the United States. In 2002, roughly 13 million Americans had CHD; Ͼ2 million of them were hospitalized with the disease. In 2005, the estimated direct and indirect costs of CHD are in excess of $142 billion. 1 Clearly, CHD and its prevention remain important health concerns.
Hypercholesterolemia is a major risk factor for CHD. Although mean serum total cholesterol concentrations have dropped in the United States in recent decades, Ϸ50% of adults (Ն20 years old) have total cholesterol concentrations of at least 5.18 mmol/L (200 mg/dL [1 mmol/Lϭ38.598 mg/dL]), 2 the level that the National Cholesterol Education Program (NCEP) expert panel considers "borderline-high risk." 3 This statistic Clinical Perspective p 3891 takes on special significance in light of recent observations that suggest that downward trends in total serum cholesterol may be flattening. 2, 4 Whether this flattening has continued into the early 2000s and whether the observed trends are consistent across all age groups are unknown. Additionally, information about the awareness, treatment, and control of hypercholesterolemia is limited but critical for understanding and improving intervention and prevention.
This report describes 20-year (1980 to 1982 through 2000 to 2002) trends in serum cholesterol; hypercholesterolemia; use of lipid-lowering drugs; and cholesterol awareness, treatment, and control with data from the Minnesota Heart Survey (MHS).
Methods
Details of the population and sampling methods have been published. [5] [6] [7] The MHS is an ongoing population-based surveillance of trends in cardiovascular disease risk factors, morbidity, and mortality in independent, cross-sectional, probability samples of adults in the Minneapolis-St. Paul, Minn, metropolitan area. Surveys were conducted in 1980 to 1982, 1985 to 1987, 1990 to 1992, 1995 to 1997, and 2000 to 2002 according to consistent sampling protocols.
Samples were selected by 2-stage cluster design. In the first sampling stage, MHS randomly selected 40 of the 704 clusters composing the 7-county metropolitan area, with each cluster containing Ϸ1000 households. Low housing growth during the 1980s allowed the initial 40 clusters to be used through 1990 to 1992. For the 1995 to 1997 survey, increased growth demanded the addition of 4 new randomly chosen clusters from among 10 high-growth clusters to maintain the population representation of the sample. Budget constraints during 1996 required early termination of the second year of sampling; therefore, bootstrap estimation was done for 26 unsampled clusters. Survey samples closely reflected the age and ethnic distributions of the 7-county metropolitan area according to 1980, 1990 , and 2000 US census information. In 1980 to 1982, the survey sample was 95.6% white and 45.8% male, whereas the metropolitan population was 94.8% white and 48.6% male. In 1990 to 1992, the survey sample was 93% white and 46.5% male, whereas the metropolitan population was 92.3% white and 49.0% male. In 2000 to 2002, the survey sample was 85.9% white and 47.2% male, whereas the metropolitan population was 84.7% white and 49.3% male.
In the second stage of each survey, a sample of households was randomly selected in each chosen cluster to generate a sample size of Ϸ5000 adults (aged 25 to 74 years for 1980 to 1982 and 1985 to 1087; aged 25 to 84 years thereafter). Only those households with at least 1 age-eligible person were included. After household enumeration, age-eligible individuals were interviewed in the home. For the 1980 to 1981, 1995 to 1997, and 2000 to 2002 surveys, all age-eligible individuals in the household were invited to participate, whereas a randomly selected individual was interviewed in other survey years. Because all analyses are sex specific and Ͼ97% of homes with 2 adults comprised opposite-sex couples, the sampling design that used all age-eligible individuals and 1 age-eligible individual per household yielded almost equivalent prevalence estimates. The home interview solicited information regarding sociodemographic characteristics; health attitudes; medical history with respect to hypertension, hypercholesterolemia, and diabetes; medications taken for these conditions; and behaviors. Subjects were then invited to a survey center where detailed questions were asked regarding medical history, smoking behavior, leisure-time physical activity during the past year, and 24-hour dietary recall. Blood pressure, height, weight, waist-to-hip ratio, and total cholesterol measures were taken. Response rates for the completed home interview, clinic visit, and overall (in that order) were 91%, 77%, and 69% (1980 to 1982); 88%, 71%, and 68% (1985 to 1987); 82%, 71%, and 68% (1990 to 1992); 83%, 68%, and 65% (1995 to 1997); and 75%, 64%, and 64% (2000 to 2002). Those with a completed survey were slightly more likely to be married, employed, nonsmoking individuals with more education than nonrespondents. This research was approved by the University of Minnesota Institutional Review Board, and informed consent was collected from all participants.
Height was measured in stocking feet with a wooden triangle and a rigid ruler attached to a wall. Weight was measured without coat and shoes with a beam balance; the balance was calibrated daily with a 22.68-kg (50-lb) weight. Body mass index was calculated as weight (kg) divided by the square of height (m 2 ). Current smoking was defined as having smoked Ͼ100 cigarettes in a lifetime and smoking currently. Leisure-time physical activity was measured with the Minnesota Leisure-Time Physical Activity Questionnaire 8 in a 50% systematic sample of participants (ie, every other participant listed on the scheduling log). In the 2000 to 2002 survey, physical activity measures were collected for all participants. The questionnaire queried participants on Ϸ63 leisure-time activities, the number of times the activity was performed per month, and the number of months the activity was performed during the past year.
Alternate participants who did not complete the leisure-time questionnaire completed a 24-hour dietary recall administered by trained, certified interviewers (except during 2000 to 2002, when all participants completed the recall). The same food database was used for all surveys, although new foods were added so that the energy and nutrient composition of diets was accurately quantified according to the current food supply. 4, 9 Nutrient intakes were estimated with the University of Minnesota Nutrition Coordinating Center Food and Nutrient Database. 10 Serum total cholesterol was measured in nonfasting samples with an AutoAnalyzer II (Technicon Corporation) with a nonenzymatic method between 1980 to 1982 and 1990 to 1992 and with an enzymatic method thereafter. The analytical laboratories participated successfully in the Centers for Disease Control and Prevention cholesterol standardization programs for all surveys. Between 1980 to 1982 and 1990 to 1992, laboratory drift assessment did not correctly adjust cholesterol levels. Therefore, we recalibrated the first 3 surveys against the reference Abell-Kendall method (ϩ0.17 mmol/L for 1980 to 1982; ϩ0.22 mmol/L for 1985 to 1987; and Ϫ0.11 mmol/L for 1990 to 1992; PϽ0.001 for all). 11 The Abell-Kendall method-adjusted cholesterol concentrations for the first 3 surveys were used in this analysis. The enzymatic method produced results equivalent to the reference method. 4 Laboratory quality-control coefficient of variance estimates for total cholesterol were generally between 1.2% and 2.8% throughout the study, and 93% of all coefficient of variance estimates for total cholesterol were Ͻ3%. HDL (high-density lipoprotein) cholesterol was measured with an enzymatic method after precipitation of non-HDL cholesterol with heparin and Mn 2ϩ (1980 to 1992) 12 or magnesium dextran sulfate (1995 to 2002). 13 Because of difficulties associated with the intercalibration of these 2 methods, HDL is reported here for 1995 to 2002 only.
Hypercholesterolemia was defined as either a serum total cholesterol concentration Ն5.18 mmol/L or answering affirmatively to the question, "Are you currently taking medication prescribed for you by a doctor for high blood fats?" Patients with controlled hypercholesterolemia were defined as those taking lipid-lowering medication and having a serum total cholesterol concentration Ͻ5.18 mmol/L. For comparison with previous studies, the prevalence of hypercholesterolemia was also calculated from a Ն6.21 mmol/L cutpoint.
Data were analyzed with SAS analytic software (SAS Institute, Inc). 14 All analyses were sex specific. The means and frequencies of study variables were calculated for each survey period and for 10-year age groups. Only participants aged 25 to 74 years were included in this analysis. To compute unbiased variances of the sample means, we took into account the neighborhood cluster design, adding the neighborhood cluster as a random-effect term. Two statistical tests were used to characterize temporal trends. Restricted maximum-likelihood regressions were used to test for overall linear trends through the duration of the study. ANCOVA was used to test for differences between temporally adjacent surveys.
Results
Descriptive characteristics of the study samples are shown in Table 1 . We found no clustering within household for ancillary risk factors such as smoking and leisure-time physical activity. When adjusted for age, cholesterol intake, lipid-reducing drug use, and body mass index, serum total cholesterol estimates were virtually the same as those generated by the age-adjusted-only model; therefore, we report age-adjusted values here.
Serum Total Cholesterol
Total cholesterol concentrations for men and women are shown in Figure 1 . Age-adjusted mean total cholesterol in 2000 to 2002 was 5.16 and 5.09 mmol/L for men and women, respectively. Age-adjusted means for both men and women showed significant (PϽ0.0001) downward linear trends from 1980 to 1982 to 2000 to 2002. In both men and women, age-adjusted mean total cholesterol also decreased significantly (PϽ0.05) between each temporally adjacent survey except for 1990 to 1992 to 1995 to 1997, when there were no significant changes. In men, from 1980 to 1982 to 1995 to 1997, total cholesterol was highest in either the 45-to 54-or the 55-to 64-year-olds, but more recently (2000 to 2002), the 35-to 44-year-olds showed the highest concentration. In women, total cholesterol was highest in 65-to 74-year-olds in each survey. In both men and women, all age groups except 25-to 34-year-olds showed significant (PϽ0.05) 20-year linear decreases. The 25-to 34-year-old men and women showed no overall change in total cholesterol across the 5 survey periods. Figure I 
Serum HDL Cholesterol
Serum HDL data for 1995 to 2002 are shown in Table 2 . Age-adjusted mean (ϮSE) HDL cholesterol concentrations for men were 1.11Ϯ0.0098 in 1995 to 1997 and 1.09Ϯ0.012 in 2000 to 2002. Age-adjusted mean HDL cholesterol concentrations for women were 1.40Ϯ0.012 in 1995 to 1997 and 1.40Ϯ0.014 in 2000 to 2002. Figure 2 shows sex-specific, age-adjusted mean and 10-yearage-group hypercholesterolemia trends. With the Ն5.18mmol/L definition, the age-adjusted mean hypercholesterolemia prevalence in 2000 to 2002 was 54.9% for men and 46.5% for women (23.9% and 17.3% for men and women, respectively, with the Ն6.21-mmol/L cutpoint). None of these values varied significantly (PϽ0.05) from the 1995 to 1997 survey. The age-adjusted mean prevalence of hypercholesterolemia defined by a Ն5.18-mmol/L threshold showed significant, downward, study-long linear trends for both men and women; with the Ն6.21-mmol/L cutpoint, neither men nor women showed a significant overall trend in age-adjusted means (see Figure II in the Data Supplement). The ageadjusted mean prevalence of hypercholesterolemia (Ն5.18- 1980 -1982 1985-1987 1990 -1992 1995-1997 2000 -2002 1980 -1982 1985-1987 1990 -1992 1995-1997 2000 -2002   n  1588  2193  2174  2706  1210  1777  2353  2356  3048 mmol/L cutpoint) decreased when those taking lipid-lowering drugs were omitted (see Figure III in the Data Supplement); this analysis may underestimate the true prevalence of hypercholesterolemia because most of those taking such drugs would have hypercholesterolemia if they were untreated.
Prevalence of Hypercholesterolemia

Prevalence of Lipid-Reducing Drug Use
The age-adjusted prevalence of lipid-reducing drug use is shown in Figure 3 . In both men and women, drug use has shown a significant (PՅ0.002), linear 20-year increase in all age groups except 25-to 34-year-olds. Successively older age groups have generally had higher frequencies of lipidreducing drug use.
Cholesterol Awareness, Treatment, and Control
Sex-specific, age-adjusted trends in the fraction of hypercholesterolemic participants who where aware of their cholesterol level, were pharmacologically treating their hypercholesterolemia, and were controlling their cholesterol (ie, successfully reducing total cholesterol to Ͻ5.18 mmol/L) are shown in Figure 4 . The fraction of both men and women who were unaware of their hypercholesterolemia continued to drop to Ϸ53% to 55% in 2000 to 2002. Of those individuals aware of their hypercholesterolemia, an increasing percentage in 2000 to 2002 were successfully treating their condition (13.1% of men, 6.0% of women). The percentage of both sexes who were aware of but unsuccessfully treating their cholesterol remained at Ϸ6% for the 2 most recent surveys. Those aware of their hypercholesterolemia but who were not undergoing treatment has been relatively stable in men (28%) and women (30% to 33%) since 1990 to 1992. 
Discussion
Serum Total Cholesterol
The recent data suggest that the apparent flattening of the downward trend in total cholesterol (from 1990 to 1992 to 1995 to 1997) did not continue into 2000 to 2002; ageadjusted mean concentrations have again declined for both sexes. This extends the trend of generally declining serum total cholesterol concentrations observed nationally since 1960. 4 -7,15-21 Decreases in total cholesterol-both 20-year trends and adjacent-survey differences-are not, however, uniform across age groups (Figure 1 ). Most obviously, neither young (25 to 34 years) men nor young women have shown any significant trends in total cholesterol across the study, and in the past decade, both have posted at least 1 significant (PϽ0.05) adjacent-survey increase. Differences in trends among other age groups are more difficult to characterize. In women, the 3 oldest age groups (45 to 74 years) all showed significant declines in total cholesterol in the most recent survey, but the 2 youngest showed either no change (35 to 44 years) or an increase (25 to 34 years). The situation is similar, albeit not as simple, in men. The 3 oldest age groups (45 to 74 years) also showed significant recent declines. As in women, total cholesterol in 35-to 44-year-old men did not change significantly from 1995 to 1997 to 2000 to 2002. (This group showed nonsignificant increases during this period.) The 25-to 34-year-old men did show a recent significant adjacent-survey decline; this, however, came after a 1990 to 1992 to 1995 to 1997 increase. Taken together, these age-specific observations suggest that the rate of total cholesterol decline in the population may vary across ages, with older (and generally higher total cholesterol) groups showing a potentially more precipitous decrease.
We compared the MHS results with the National Health and Nutrition Examination Survey (NHANES) values. Although the mean MHS total cholesterol estimates for 2000 to 2002 are lower than the NHANES values for 1999 to 2000 for both men (MHS, 5.16; NHANES, 5.25 mmol/L) and women (MHS, 5.09; NHANES, 5.28 mmol/L), 2 the trend in cholesterol in Minnesota has mirrored national trends. MHS cardiovascular risk factor trends have historically been harbingers of national trends. If these trends continue as they have in the past, 6, 15 the recent flattening in national total cholesterol trends may also prove temporary. There are no other serial cross-sectional surveys in the United States that have collected both hypercholesterolemia and serum measures of cholesterol with which MHS data can be compared.
Serum HDL Cholesterol
Because of MHS changes in HDL measurement methods between the 1980 to 1992 and 1995 to 2002 survey periods, we were unable to comprehensively evaluate the long-term trends in HDL cholesterol. Unlike total cholesterol, there is Adjacent-survey significant differences are not shown. Figure 4 . Cholesterol awareness, treatment, and control for hypercholesterolemic (Ն5.18 mmol/L or taking lipid-reducing drugs) men and women. Groups include those aware of, treating, and controlling their hypercholesterolemia; those aware, treating, but not controlling; those aware, but not treating and not controlling; and those unaware of their hypercholesterolemic status.
no "gold standard" measurement for HDL cholesterol that provides a benchmark against which to normalize periodspecific HDL values. Between 1995 to 1997 and 2000 to 2002, when HDL was measured with a magnesium dextran sulfate precipitate, there were no significant changes in HDL cholesterol in the population of Minneapolis-St. Paul. The pattern of HDL showed that younger women tended to have lower concentrations of HDL; however, age-related trends in men were not as clear.
Prevalence of Hypercholesterolemia
The overall population decrease in serum cholesterol concentrations since 1980 is reflected in the small but significant declines in the prevalence of hypercholesterolemia, defined as total cholesterol Ն5.18 mmol/L or using lipid-reducing drugs. If the lipid-reducing drug criterion is removed from the definition of hypercholesterolemia ( Figure III in the Data Supplement), the mean prevalence of hypercholesterolemia has shown steeper downward trends in both men and women during the course of the study, although this method of analysis may underestimate prevalence by omitting treated people who would have been hypercholesterolemic if they were untreated. The MHS 2000 to 2002 age-adjusted, mean, measured hypercholesterolemia prevalence figure for men is similar to the 1999 to 2000 national finding (MHS, 54.9%; NHANES, 55.7%; the MHS figure for women, however, is considerably lower than the national finding [MHS, 46.5%; NHANES, 53.5%]). 2 The difference in women in Minnesota from the national sample may be due to the higher level of education in Minnesota women and their access to medical care relative to the general US population. This is supported by Behavioral Risk Factor Surveillance System (BRFSS) data (from 1995 to 2002 only) that suggest that improvements in education for Minnesota men is generally closer to the national trend for men than Minnesota women are to the national trend for women. The same is true for access to health care: Minnesota women are generally outpacing Minnesota men in gains on the national average for healthcare access (BFRSS data at http://apps.nccd.cdc.gov/brfss/).
Factors Affecting Serum Cholesterol Trends
The large increase in the use of lipid-reducing drugs observed in this study is comparable to the pattern described for US retail pharmacies: The number of lipid-reducing medications dispensed nearly doubled between 1991 and 1997. 22 The dramatic increase in the use of lipid-reducing drugs since 1980 to 2002 ( Figure 3) invites an analysis of the effects of this trend on total cholesterol and the prevalence of hypercholesterolemia. A comparison of total cholesterol concentrations in the entire MHS population with total cholesterol of those not taking lipid-reducing drugs ( Figure I in the Data Supplement) shows that trends have generally been quite similar in the drug-taking versus entire MHS sex and age groups; however, recent data suggest potentially important differences. In the 2000 to 2002 survey, 45-to 74-year-old men and 65-to 74-year-old women in the total MHS population (ie, including those taking lipid-reducing drugs) showed a steeper downward trend in total cholesterol concentrations than those in the nonmedicated population. These trends suggest that the higher prevalence of lipid-reducing drug use in older age groups may be partially responsible for these groups' continued reduction of total cholesterol. In the absence of adoption of lipid-lowering therapy by a large segment of the population, the downward trends in total cholesterol would be less dramatic. This observation highlights the challenge of the use of a composite hypercholesterolemia definition in assessing population trends, because the definition reflects the mixture of prescription drug use and the laboratory cholesterol value. Therefore, the trend in the "true" level of cholesterol in the population unconfounded by treatment cannot be ascertained.
Cholesterol Awareness, Treatment, and Control
Increases in the awareness, treatment, and control of hypercholesterolemia are encouraging; however, more than half of those at or above borderline-high risk remain unaware of their condition (Figure 4 24, 25 MHS data suggest that bridging the gap between screening and control remains an important public health goal. In 2000 to 2002, awareness, treatment, and control rates were all lower in women than in men; in fact, the percentage of hypercholesterolemic women successfully controlling their cholesterol (6.0%) was less than half that of men (13.1%). Although control rates have increased through the MHS study, this ratio has been observed since 1990 to 1992 and mirrors the difference observed in the most recent NHANES sample (7.5% for men, 3.7% for women). Sex bias in lipid management has been documented in other studies 26 -28; however, the causal factors leading to this bias remain unclear. 29, 30 
Study Limitations
Our definition of hypercholesterolemia based on total cholesterol rather than low-density lipoprotein cholesterol may be viewed as a limitation of the study. However, the differential risk levels associated with total cholesterol's constituent components were not as firmly established when MHS was begun as they are today, and validated analytic methods for low-density lipoprotein were not developed until recently. These historical constraints, combined with the that fact total cholesterol can be reliably measured in fasting or nonfasting samples 31, 32 and that NCEP sanctions the use of nonfasting total cholesterol measurements for making initial health management decisions, 3 explain and legitimize our choice of using total cholesterol throughout the study. The overall response rate for the MHS survey declined slightly during the 20-year period. It should be noted that we calculated a true response rate, wherein the denominator was inflated to account for the number of households that we were unable to contact or that had members who refused to participate, multiplied by the average number of eligible individuals in a household. It is unlikely that the 5% drop in participation resulted in a significant bias in the observed cholesterol trends, because the sample survey closely matched the age and ethnic distributions of the Minneapolis-St. Paul population at large at each survey period.
Because of the number of statistical tests performed in these analyses and because we made no adjustments for multiple testing, some caution must be taken when interpreting our reported probability values. Because Minnesota ranks lowest among US states in age-adjusted death rates for total cardiovascular disease, 1 MHS data may serve better as a point of comparison rather than a basis for generalization for cardiovascular risk factor trends in the wider population.
Public Health Implications
Mean serum total cholesterol concentrations have continued a 20-year decline in the Minneapolis-St. Paul population, punctuated by an intervening lull. However, this trend has not been uniform across all age groups. Although middle-aged to older people (45 to 74 years) have shown substantial decreases, younger (25 to 44 years) people have shown little overall change and have, in fact, recently experienced increased total cholesterol concentrations. Although the prevalence of untreated hypercholesterolemia has continued to fall, significant segments of the population still have serum cholesterol concentrations near or at the NCEP level of borderline-high risk. The greater than one half of the population who remain unaware of their hypercholesterolemic status points to the continued need for improved screening. The MHS data reinforce that improved screening alone, however, is insufficient; we must continue to encourage behavioral, dietary, and pharmacological control of cholesterol in those individuals who are aware of their cholesterol risk.
